230 results about "Human breast" patented technology

The invention discloses a PARP1 / CDK6 double-target inhibitor as well as a preparation method and application thereof, the PARP1 / CDK6 double-target inhibitor is selected from a compound with a structure as shown in a formula I or pharmaceutically acceptable salt or solvate thereof, L is selected from # imgabs0 #, and R is selected from hydrogen, deuterium, halogen, hydroxyl, sulfydryl, cyano, nitro, methoxyl, C1-C8 alkyl or C3-C8 cycloalkyl. The PARP1 / CDK6 double-target inhibitor disclosed by the invention has a relatively good effect on human breast cancer cells, and keeps good in-vitro enzyme inhibition activity on CDK6 and PARP1. The invention discloses an application of a CDK6 / BRD4 double-target inhibitor in preparation of a medicine for treating PARP1 / CDK6 mediated diseases. The invention discloses an application of a PARP1 / CDK6 double-target inhibitor in preparation of a medicine for treating or preventing triple negative breast cancer. # imgabs1 #

The invention discloses a breast adenoma B3 type source cell strain as well as construction and application thereof, the breast adenoma B3 type source cell strain is named as human breast adenoma cell Hthy2301 Homo sapiens and is preserved in China Center for Type Culture Collection on March 14, 2024, and the preservation number is CCTCC NO: C202478. The human thymoma cell line is stable in character, can be passaged in vitro for a long time, and has high proliferation activity. The human thymoma cell line disclosed by the invention can be used as an effective cell model, and a new experimental model can be provided for deeply researching the occurrence, development and transfer mechanisms of thymoma, the drug resistance mechanism, drug screening, drug effect evaluation and the like.

The invention relates to a triple-hole paper-based three-dimensional cell culture chip as well as a preparation method and application thereof. The chip comprises a paraffin hydrophobic region and a paper-based hydrophilic region. The preparation method mainly comprises the following steps: 1) designing a mask plate; 2) cutting the mask plate by laser; and 3) preparing the triple-hole paper-based chip by hot pressing. The thickness of the chip is 100-200 [mu] m, the porous fiber structure of the paper-based material allows transportation of oxygen and waste, and a three-dimensional microenvironment for in-vivo cell growth can be simulated. Meanwhile, a transparent and liquid-tight supporting layer is fused on the lower layer of the paper-based chip, so that leakage of cells inoculated on the upper layer of the paper-based chip is avoided. The paper-based chip is embedded into a 6-pore plate, and bladder cancer cells (5637), mouse astrocytoma (U87) and human breast cancer cells (MCF-7) are inoculated in a paper-based hydrophilic region respectively. The cell compatibility of the paper-based chip and the growth behaviors of three different types of cells in three-dimensional paper fibers are investigated. It is proved that the chip can be used for researching three-dimensional construction and growth of human and mammalian cells, and the difference between three-dimensional culture and two-dimensional culture is revealed by detecting the proliferation capacity and survival rate of different cells.

The invention provides a beta '-sulfo-alpha, beta-unsaturated gamma-lactam derivative as well as a preparation method and application thereof, and belongs to the technical field of organic chemical synthesis. The beta '-thio-alpha, beta-unsaturated gamma-lactam derivative has a structure as shown in a formula I. According to the method disclosed by the invention, cesium carbonate is taken as alkali, and a molecular skeleton of the beta'-thio-alpha, beta-unsaturated gamma-lactam derivative is constructed through free radical coupling and olefin isomerization processes under the condition of blue light irradiation. Bioactivity evaluation shows that the beta '-sulfo-alpha, beta-unsaturated gamma-lactam derivative prepared by the method disclosed by the invention has an inhibition effect on MDA-MB-231 human breast cancer cells.

The invention discloses a construction method and application of a ratio-dependent electrochemical luminescence (ECL) biosensor based on an antifouling red cell membrane, and belongs to the technical fields of photoelectric analysis, biosensing and interface antifouling. In the invention, the erythrocyte membrane with super-hydrophilicity and low membrane protein content is used as an efficient antifouling interface, and the good biocompatibility of the erythrocyte membrane avoids the influence of a chemical antifouling coating on the biological activity of the ECL sensor. Meanwhile, the electropolymerized polyaniline nanowire is embedded into the antifouling erythrocyte membrane, so that the chemical stability and the conductivity of the antifouling erythrocyte membrane are enhanced, and the application of the antifouling erythrocyte membrane in ECL analysis is expanded. C3N4 is introduced as an interior label for eliminating background signals and external interference, so that the detection precision of the biosensor is improved. On the basis, the constructed ECL antifouling biosensor realizes ultra-sensitive detection of human breast cancer cells MCF-7 in human serum, and the detection limit is as low as 3 cells / mL.

The invention discloses a heterocyclic compound and application thereof. The invention provides a compound as shown in a formula (I), a tautomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a solvate of the pharmaceutically acceptable salt thereof. The heterocyclic compound provided by the invention shows a good cell growth inhibition effect on tumor cell strains of human breast cancer cells HCC1569 and human ovarian cancer cells OVCAR3, and the compound provided by the invention can be used as a PKMYT1 inhibitor. # imgabs0 #

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a 3-sulfamoyl benzamide compound as well as a preparation method and application thereof. The 3-sulfamoyl benzamide compound has a structure as shown in a formula I. In the formula I, X is chlorine or trifluoromethyl; r1 and R2 are independently C1-4 alkyl or R1, R2 and N atoms connected with R1 and R2 jointly form a heterocyclic group, and the heterocyclic group is a substituted or unsubstituted five-membered or six-membered heterocyclic group; and when the heterocyclic group is a substituted heterocyclic group, the substituent group in the substituted heterocyclic group is one or more of C1-4 alkyl, phenyl and acetyl. The 3-sulfamoyl benzamide compound disclosed by the invention has a remarkable proliferation inhibition effect on HCT116 colon cancer cells, HeLa human cervical cancer cells, MDA-MB-231 human breast cancer cells and A375 human malignant melanoma cells.

The present invention belongs to the technical field of undergarments, and discloses a brassiere, which includes a pair of bra cup cores, and one or more body fabric panel attached with the bra cup cores on the front. The brassiere is formed by connecting both sides via side band fabric panel which are warped to a back of the body, and is sealed and fastened via fastening buckles with or without shoulder straps or fabric panel to support, uplift, and control human breasts. The present invention aims at restoring natural and comfortable beauty of the human breasts via the seamless brassiere fused with the bra cup cores with the 3D bonding technology to minimize joining and stitching causing the itch or discomfort for wearers. The 3D bonding technology of the present invention can be used for the shapes, profiles, and peripheries of different types of 3D bra cup core.

Disclosed is an anticancer composition using a flavone derivative. In the present invention, the flavone derivative exhibits cytotoxicity against: H827, H1299, H522, and A549, which are human non-small cell lung cancer cell lines; MCF-7, which is a human breast cancer cell line; and PANC-1, which is a human pancreatic cancer cell line, in a time-dependent manner and in a treatment concentration-dependent manner, and not only exhibits a synergistic effect when used in combination with other conventional anticancer agents, such as osimertinib, which is an anticancer agent targeting for lung cancer, tamoxifen, which is a hormone agent against breast cancer, and gemcitabine, which is a cytotoxic anticancer agent against pancreatic cancer, but also exhibits the effect of synergistically inhibiting the expression of HIF-1α when used alone or in combination with an existing anticancer agent.

The invention discloses a 5-substituted-3-(arylaminoethyl) benzoxazolone compound and a preparation method and application thereof.The compound takes CO2 as a carbonyl source, the preparation method is simple, raw materials are easy to obtain, and the compound has a good anti-cancer effect on the activity of cancer cells and particularly has a remarkable anti-cancer effect on the cancer cells such as HCCLM3 (human hepatoma carcinoma cells) and MCF-7 (human breast cancer cells).

The invention discloses a diosgenin derivative containing a 1, 2, 3-triazole structure fragment as well as a preparation method and application of the diosgenin derivative, and belongs to the field of natural medicinal chemistry and medicinal chemistry. Based on a molecular heterozygosis principle, diosgenin is used as a lead compound and is heterozygous with a 1, 2, 3-triazole structure fragment with different substituent groups to obtain a derivative shown as a general formula (I) or (I). The diosgenin derivative containing the 1, 2, 3-triazole fragment, disclosed by the invention, has good anti-breast cancer activity. Pharmacological experiment results show that the anti-tumor activity of part of the derivatives on human breast cancer cells is obviously superior to that of diosgenin, and the toxicity on human normal gastric mucosa epithelial cells is relatively small, so that the derivatives are expected to be further developed into anti-tumor drugs. # imgabs0 #

The invention relates to the technical field of cell engineering, in particular to a breast cancer carboplatin drug-resistant cell strain and a construction method thereof, the breast cancer carboplatin drug-resistant cell strain is preserved in Guangdong Microbial Culture Collection Center on October 16, 2024, the preservation number is GDMCC No: 6528, and the preservation number is CGMCC NO: 6528. The drug-resistant cell strain MDA-MB-231 / CBP constructed in the invention can stably grow and pass in a carboplatin culture system with an action concentration of 20 [mu] M, has a carboplatin resistance index (RI) of 10.7, provides a basis for research of a carboplatin drug-resistant mechanism and development of related targets, and has a wide application prospect. The invention provides a drug-resistant cell model for researching the drug resistance mechanism of human breast cancer cells to carboplatin, searching an effective treatment method for overcoming human breast cancer drug resistance, preparing antitumor drugs, screening tumor drug resistance reversal drugs, guiding clinical medication and the like, and has important effects and good application prospects.

A method of treating cancer cells includes exposing the cancer cells to a ZrO2 / CaSiO3 / g-C3N4 nanocomposite material. The ZrO2 / CaSiO3 / g-C3N4 nanocomposite material comprises spherical metal oxide nanoparticles comprising a ZrO2 phase and a CaSiO3 phase dispersed on a matrix of g-C3N4 nanosheets, wherein the spherical metal oxide nanoparticles have an average particle diameter in a range from 3 to 18 nm, and wherein the ZrO2 / CaSiO3 / g-C3N4 nanocomposite material has a percent inhibition for human breast carcinoma (MCF-7) cells greater than or equal to 80% inhibition in an in-vitro cellular viability assay.

The invention discloses a capsaicin compound and a preparation method and application thereof, the molecular formula of capsaicin Capsivaryine is C16H21NO3, the chemical structure of capsaicin Capsivaryine is as follows, and the capsaicin Capsivaryine compound is a new compound reported for the first time and is prepared by taking mature and dry fruits of capsicum as raw materials through crushing, sieving, silica gel column treatment, D101 macroporous resin treatment and HPLC (High Performance Liquid Chromatography). The compound disclosed by the invention has a certain in-vitro inhibition effect on human breast cancer cells MCF-7, human liver cancer cells HEPG2, human non-small cell lung cancer cells A549 and human ovarian cancer cells SKOV3, and has no toxicity on human normal liver cells L02. The compound is a natural product which is novel in structure and good in activity, has great potential in the anti-tumor aspect, enriches diversity of pepper plants, and provides guidance for research of chemical components of pepper. # imgabs0 #

The invention discloses benzo [4, 5] imidazo [2, 1-a] isoquinoline compounds as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The benzo [4, 5] imidazo [2, 1-a] isoquinoline compound can be used for preparing anti-tumor (human breast cancer) drugs, the structure of the benzo [4, 5] imidazo [2, 1-a] isoquinoline compound is shown in the specification, in the formula, R1 is any one or two of hydrogen, halogen, alkyl, alkoxy, fused ring and aryl; r2 is any one of hydrogen, halogen, alkyl and alkoxy; and R3 is any one or two of hydrogen, halogen, alkyl and alkoxy. The preparation method of the compound comprises the following steps: by taking palladium acetate and norbornene as catalysts, tris (4-chlorphenyl) phosphine and the like as ligands, potassium carbonate and the like as alkali and 1, 4-dioxane as a solvent, carrying out one-pot synthesis on a 1-(2-bromo-1-phenyl vinyl) benzimidazole compound and an iodobenzene compound in an argon atmosphere. Structure of compound: # imgabs0 #

The invention discloses a single molecule detection kit for a plurality of non-coding RNAs (Ribonucleic Acid) in human breast tissues by using a programmable automatic cascade mechanism and application of the single molecule detection kit. The preparation method of the single molecule detection kit comprises the following steps: incubating piRNA-36026, lncRNA-DSCAM-AS1, a dumbbell probe-pi, a dumbbell probe-lnc, a primer-pi, a primer-lnc, a dNTP mixed solution, a ThermoPol reaction buffer solution and a reaction solution of Bst DNA polymerase (large fragment); and adding the reaction product into a reaction solution containing the signal probe 1, the signal probe 2, an NEBuffer 4 reaction buffer solution and T7 exonuclease, and incubating to obtain the single molecule detection kit. According to the present invention, the efficient automatic cascade mechanism and the high signal-to-noise ratio single molecule detection are adopted to achieve the sensitive simultaneous detection of a variety of ncRNAs, and the high sensitivity, the good selectivity and the multi-path analysis ability are provided.

The invention discloses an azacyclo-derived polyaryl methane anti-tumor compound and a synthesis method thereof. The chemical structural formula of the compound is shown as a formula 3. The synthesis method comprises the following steps: adding 2-pyrrole derivative indole and aromatic aldehyde as reaction raw materials into toluene, stirring and reacting for 6-10 hours at 25 DEG C under the catalysis of binaphthyl phosphoric acid, tracking the reaction by TLC until the reaction is complete, filtering, concentrating and purifying to obtain the 2-pyrrole derivative indole. According to the azacyclo-derived polyaryl methane compound synthesized by the invention, a biological activity test shows that the derivative has relatively high sensitivity and very strong cytotoxic activity on human breast cancer cells MCF-7. The method is conventional in reaction condition, mild and simple in reaction process, low in cost and suitable for industrial large-scale production, and the application range of the method is widened; according to the method, various substrates are used as reactants, and products with various structures are obtained. # imgabs0 #

The invention belongs to the technical field of machine learning, and provides a multi-model integrated prediction method and system for human breast cancer cytotoxicity caused by ionic liquid, and the main scheme is as follows: collecting experimental data and preprocessing the experimental data; splicing the quantifiable features to form an original feature matrix; performing feature dimension reduction processing on the original features to form an input feature matrix; taking the input feature matrix as input data, training a random forest, XGBoost and MLP basic machine learning model and carrying out model parameter adjustment, carrying out model integration on the trained basic machine learning model based on a weighted average fusion strategy, and selecting an optimal integrated model; evaluating the trained basic machine learning model, and applying the optimal integrated model to prediction of the human breast cancer cell toxicity of the ionic liquid of a new sample; and carrying out model deployment on the trained basic machine learning model and the selected optimal integrated model.

The invention relates to preparation of a novel indole camptothecin derivative and an application of the novel indole camptothecin derivative in an anti-tumor aspect. The structural general formula of the compound is shown in the specification. In-vitro cytotoxic activity screening results show that the novel indole camptothecin derivative has broad-spectrum antitumor activity, and shows relatively strong inhibitory activity on human liver cancer cells (HepG2), human non-small cell lung cancer cells (A549), human colon cancer cells (SW480), human intrahepatic bile duct cancer cells (RBE), human breast cancer cells (MCF-7), human pancreatic cancer cells (BxPC3), human bladder cancer cells (T24) and human bladder cancer cells (umuc3). Wherein the anti-tumor activity of the compound D-18 is the most prominent, the compound D-18 shows a relatively strong inhibition effect on the tested 8 tumor cell lines, the IC50 range is 0.2585-10.69 mu M, the compound D-18 is obviously superior to that of a contrast drug irinotecan, and the activity of the compound D-18 is equivalent to that of topotecan. Therefore, the indole camptothecin derivative is expected to be developed into a novel antitumor drug. # imgabs0 #

The application belongs to the technical field of medicine, and relates to N-methyl-2-(9-oxoacridin-10(9H)-yl)acetamide compounds and a preparation method and application thereof. The preparation method of the compound is as follows: taking o-aminobenzoic acid as a starting material, performing substitution reaction, condensation reaction, alkylation reaction and hydrolysis reaction to generate a key intermediate acridone acetic acid, and finally performing condensation reaction on the acridone acetic acid and substituted pyrimidine in the presence of TCFH and NMI condensing agents to obtain the target compound. The preparation method of the N-methyl-2-(9-oxoacridin-10(9H)-yl)acetamide compound provided in the application is simple and feasible, and good results are shown in in-vitro anti-tumor activity tests, and the compound has excellent anti-proliferation ability on human breast cancer cells BT-549 and MDA-MB-231 in particular.

The invention belongs to the technical field of pharmacy, and particularly relates to application of polycyclic alkaloid in preparation of an anti-breast cancer drug, and the polycyclic alkaloid is 1, 2a, 7-trimethyl-5-tosyl-1, 2, 2a, 3, 4, 5-hexahydropyrrolo [4, 3, 2-de] quinoline. The polycyclic alkaloid compound is applied to preparation of anti-breast cancer drugs, the effect of inhibiting growth of breast cancer cells is remarkable, and the efficacy of the polycyclic alkaloid compound is far better than that of a positive drug ML162 aiming at EC50 (mu M) + / -S.D = 9.04 + / -0.37 of HCC1937 human breast cancer cells.

The utility model discloses underwear which comprises a first part and a second part, the first part is located on the front side of a human body when the underwear is used, and the second part is located on the rear side of the human body when the underwear is used. The first part comprises a first fabric piece, a lining piece and a bottom surrounding piece, the second part comprises a second fabric piece, the lining piece is located between the first fabric piece and the second fabric piece, an inner pocket penetrating through the thickness of the lining piece is formed in the lining piece, and the inner pocket is formed in the position corresponding to a nipple or an areola of a human breast. According to the underwear, the inner pockets penetrating through the thickness of the lining piece are formed in the lining piece, so that when the underwear is used, the chest part penetrates through the inner pockets, meanwhile, the part, close to the inner pockets, of the lining piece is attached to the surfaces of the breasts to support and wrap the breasts, elasticity and constraint of the fabric are utilized, other parts are not needed, and the underwear is comfortable, free of feeling and free of stuffy sweat.

The invention discloses an application of an ARRB1 inhibitor in preparation of a tumor drug resistance reversal agent or a tumor drug sensitizer. It is found that by reducing ARRB1 expression, the sensitivity of human breast cancer cells to etoposide can be improved, the drug resistance of breast cancer etoposide can be reversed, and an ARRB1 inhibitor can be combined with an anti-tumor drug etoposide for use to improve the treatment effect. The invention provides a new direction for research and development of drugs for overcoming breast cancer treatment drug resistance, and has important clinical application value and development value.

A method of inhibiting a cancer cell growth includes contacting the cancer cell with a Cu2(OH)3NO3 / CaSiO3@g-C3N4 nanocomposite material containing graphitic carbon nitride (g-C3N4), copper hydroxide nitrate (Cu2(OH)3NO3) and calcium silicate (CaSiO3), achieving an inhibition efficiency on human breast carcinoma (MCF-7) and human hepatocellular carcinoma (HepG-2) cell growth of greater than 95% in an in-vitro cellular viability assay.

The BTK-C isoform is expressed in human breast and prostate cancer cells and it plays a crucial role in epithelial cancer cell survival. BTK-C has a 34 amino acid extension to the n-terminus that facilitate it being palmitoylated on two cysteine residues. This modification localizes BTK-C closer to the cell membrane where it plays a role in improving cancer cell survival, as compared to BTK-A. BTK-C is not found to be expressed in healthy adult cells, whereas BTK-A is necessary for immune cell production. Disclosed herein are alternative kinases besides BTK having similar attributes, which present therapeutic opportunities for the treatment of cancers, especially for solid tumors.

The invention discloses a breast pump. The breast pump comprises at least one detection module, a processing module, a breast pumping shield, a breast pumping channel part and a negative pressure mechanism, the breast suction shield comprises a flange used for being attached to a human breast body. The breast sucking channel part is in sealed connection with the breast sucking shield and is used for accommodating a nipple and allowing milk to flow; the negative pressure mechanism is used for directly or indirectly applying negative pressure into the breast pumping channel part; the detection module is used for detecting brightness change caused by movement of a target object in the breast pumping shield or the breast pumping channel part and generating detection data, and the processing module is used for determining breast pumping related parameters according to the detection data. The detection module generates the detection data by detecting the brightness change caused by the movement of the target object, and the generated detection data is less influenced by the individual difference of the mother, so that the measurement interference caused by the difference of different individuals can be effectively avoided, and the finally determined breast pumping related parameters can be more accurate.

This invention relates to drug-resistant breast cancer cells and their applications, belonging to the field of tumor cell technology. The drug-resistant breast cancer cells of this invention are human mammary ductal carcinoma cells T47DR and / or human breast cancer cells MCF7R. The human mammary ductal carcinoma cells T47DR were deposited at the Guangdong Provincial Microbial Culture Collection Center on October 25, 2024, with accession number GDMCC No: 65348; the human breast cancer cells MCF7R were deposited at the same center on October 25, 2024, with accession number GDMCC No: 65347. This invention demonstrates that the clonogenic ability, migration ability, anti-apoptotic ability, and spheroidization ability of drug-resistant breast cancer cells are significantly enhanced. They can form tumors independently of estrogen and metastasize throughout the body in a short period of time. The tumor stemness of the drug-resistant cells is enhanced, and they exhibit resistance to apelexifen and / or tamoxifen.

The present invention relates to the technical field of pharmaceutical compounds and specifically discloses a selenocyanine pregnenol ketamide compound having the following general structural formula: #imgabs0#. The selenocyanine pregnenol ketamide compound of the present invention exhibits strong inhibitory activity against human breast cancer cells, cervical cancer cells, ovarian cancer cells, and human liver cancer cells. Furthermore, the selenocyanine pregnenol ketamide compound of the present invention also exhibits strong inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococci (VRE). The selenocyanine pregnenol ketamide compound of the present invention has low toxicity to humans and exhibits strong inhibitory effects against cancer cells and various drug-resistant bacteria at low concentrations. It can be used to prepare cancer treatment drugs and as an antibacterial agent against drug-resistant bacteria.

[Problem] The present invention provides an inhibitor such as an MDA-MB-231 cell proliferation inhibitor containing DHMBA as an active ingredient, the inhibitor affecting the proliferation, metastatic activity, and bone microenvironment of MDA-MB-231 cells in vitro, and making it possible to provide a useful therapeutic strategy for human breast cancer. [Solution] The present invention is characterized by having the effect of inhibiting the proliferation of human breast cancer MDA-MB-231 cells containing 3,5-dihydroxy-4-methoxybenzyl alcohol as an active ingredient.

1. The name of this design product: Breast Coil. 2. Purpose of this design product: This design product is used as auxiliary diagnostic equipment for medical imaging magnetic resonance imaging, and accurately images the types and lesions of diseases in the human breast area. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.